Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ilie Barb

Interventional Cardiology Gainesville, FL Medical Doctor

NPI 1013191105 CMS profile 136678

4645 Nw 8Th Ave, Gainesville, FL 32605

Open in the dashboard

General payments

$42,569

616 records reported · program years 2019–2025

Research payments

$6,947

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$48,917 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Ilie Barb of Gainesville, FL is reported in the CMS Open Payments database as having received $42,569 across 616 general payments and $6,947 in research payments paid to them. Separately, studies naming them as principal investigator received $48,917 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,130 77
2024 General $5,112 101
2023 General $8,020 119
2022 General $5,322 97
2022 Research $6,947 1
2021 General $2,764 44
2020 General $5,353 77
2019 General $9,868 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ilie Barb
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ilie Barb were reported at $6,130. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ilie Barb Interventional Cardiology median Middle half National median
2019 $9,868 $1,097 $329–$3,048 $163
2020 $5,353 $473 $161–$1,480 $114
2021 $2,764 $677 $233–$1,827 $132
2022 $5,322 $978 $333–$2,724 $149
2023 $8,020 $1,136 $382–$2,986 $160
2024 $5,112 $1,181 $395–$3,326 $164
2025 $6,130 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $6,852 44 payments
  2. Boston Scientific Corporation $5,429 41 payments
  3. Medtronic, Inc. $4,316 54 payments
  4. Edwards Lifesciences Corporation $3,441 39 payments
  5. Penumbra, Inc. $3,117 19 payments
  6. Medtronic Vascular, Inc. $3,014 27 payments
  7. AngioDynamics, Inc. $2,313 46 payments
  8. Amgen Inc. $1,857 44 payments
  9. Philips Electronics North America Corporation $1,826 9 payments
  10. Abiomed $1,785 17 payments
  11. Other $8,621 276 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,986 557 payments
  2. Travel and Lodging $16,833 56 payments
  3. Consulting Fee $700 1 payment
  4. Education $50 2 payments
Products named General payments · program years 2019–2025
  1. Xience V coronary stent system $2,679 6 payments
  2. Resolute $2,336 13 payments
  3. WATCHMAN $1,898 7 payments
  4. Repatha $1,732 43 payments
  5. Impella $1,524 15 payments
  6. COREVALVE EVOLUT R $1,482 15 payments
  7. Indigo $1,414 7 payments
  8. RESOLUTE ONYX $1,401 15 payments
  9. Intracardiac Undivided $1,380 4 payments
  10. Indigo System $1,283 7 payments
  11. Other $22,678 490 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $6,947 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

3,996

Median for Interventional Cardiology: 2,236

Drug cost

$1,246,851

Median for Interventional Cardiology: $380,412

Branded share of claims

47.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 321 $256,993
Entresto Sacubitril/Valsartan Brand 260 $237,937
Jardiance Empagliflozin Brand 266 $224,807
Xarelto Rivaroxaban Brand 187 $196,511
Repatha Sureclick Evolocumab Brand 194 $153,170
Multaq Dronedarone Hcl Brand 45 $47,362
Farxiga Dapagliflozin Propanediol Brand 48 $43,008
Praluent Pen Alirocumab Brand 33 $29,630
Brilinta Ticagrelor Brand 34 $17,718
Vascepa Icosapent Ethyl Brand 17 $10,390

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$609,630

Of which drugs: $2,688

Medicare patients

1,303

Average age 77

Services billed

5,395

639 women, 664 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Arthritis 56%
Atrial fibrillation 46%
Diabetes 45%
Heart failure 45%
Chronic kidney disease 43%
COPD 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 126 508 $2,675
Injection, fentanyl citrate, 0.1 mg J3010 Office 12 15 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
$180 — —
LEQVIO
$149 — —
ENTRESTO
$104 260 —
Repatha
$100 194 —
CAMZYOS
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

617 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record